Ameriprise Financial Inc. Acquires 639 Shares of argenx SE (NASDAQ:ARGX)

Ameriprise Financial Inc. grew its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 10.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,013 shares of the company's stock after acquiring an additional 639 shares during the quarter. Ameriprise Financial Inc.'s holdings in argenx were worth $4,313,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. GeoWealth Management LLC raised its stake in shares of argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after purchasing an additional 18 shares during the period. Whipplewood Advisors LLC bought a new stake in shares of argenx in the fourth quarter worth $37,000. Global Retirement Partners LLC increased its stake in shares of argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after buying an additional 48 shares during the last quarter. FIL Ltd bought a new stake in shares of argenx in the fourth quarter worth $38,000. Finally, Jones Financial Companies Lllp increased its stake in shares of argenx by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after buying an additional 61 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

argenx Trading Up 1.0%

Shares of argenx stock traded up $5.96 during trading on Thursday, reaching $582.20. The company's stock had a trading volume of 120,916 shares, compared to its average volume of 324,878. The stock has a 50-day moving average price of $587.69 and a two-hundred day moving average price of $612.60. argenx SE has a one year low of $359.37 and a one year high of $678.21. The stock has a market capitalization of $35.55 billion, a P/E ratio of -661.23 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.32 by $0.26. The firm had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, sell-side analysts anticipate that argenx SE will post 3.13 EPS for the current fiscal year.

Analysts Set New Price Targets

ARGX has been the subject of several recent research reports. Oppenheimer boosted their target price on shares of argenx from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Citigroup reiterated a "buy" rating on shares of argenx in a research note on Wednesday, May 21st. Sanford C. Bernstein raised shares of argenx from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Deutsche Bank Aktiengesellschaft raised shares of argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. Finally, William Blair reaffirmed an "outperform" rating on shares of argenx in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $709.18.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.